NCT02206711View on ClinicalTrials.gov

Study of the Absorption, Metabolism, and Route of Elimination of a Novel Class of Anti-HIV 1 Drugs (BMS-955176) in Humans.

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

August 8, 2014

Primary Completion Date

September 9, 2014

Study Completion Date

September 9, 2014

Conditions
HIV Infections
Interventions
DRUG

BMS-955176

Single dose of drug on Day 1

Trial Locations (1)

53704

GSK Investigational Site, Madison

Sponsors

Lead Sponsor

ViiV Healthcare

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

ViiV Healthcare

INDUSTRY

NCT02206711 - Study of the Absorption, Metabolism, and Route of Elimination of a Novel Class of Anti-HIV 1 Drugs (BMS-955176) in Humans. | Biotech Hunter | Biotech Hunter